Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Other Working Capital Changes: 2018-2025

Historic Other Working Capital Changes for Whitehawk Therapeutics (WHWK) over the last 8 years, with Sep 2025 value amounting to $817,000.

  • Whitehawk Therapeutics' Other Working Capital Changes rose 556.42% to $817,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$297,000, marking a year-over-year increase of 91.83%. This contributed to the annual value of -$2.8 million for FY2024, which is 21.90% up from last year.
  • Whitehawk Therapeutics' Other Working Capital Changes amounted to $817,000 in Q3 2025, which was up 679.43% from -$141,000 recorded in Q2 2025.
  • In the past 5 years, Whitehawk Therapeutics' Other Working Capital Changes registered a high of $1.6 million during Q4 2021, and its lowest value of -$1.7 million during Q3 2023.
  • Its 3-year average for Other Working Capital Changes is -$591,455, with a median of -$765,000 in 2025.
  • Per our database at Business Quant, Whitehawk Therapeutics' Other Working Capital Changes surged by 3,315.69% in 2021 and then slumped by 2,603.64% in 2023.
  • Whitehawk Therapeutics' Other Working Capital Changes (Quarterly) stood at $1.6 million in 2021, then crashed by 107.01% to -$115,000 in 2022, then crashed by 794.78% to -$1.0 million in 2023, then spiked by 79.79% to -$208,000 in 2024, then surged by 556.42% to $817,000 in 2025.
  • Its Other Working Capital Changes was $817,000 in Q3 2025, compared to -$141,000 in Q2 2025 and -$765,000 in Q1 2025.